Corbus Pharmaceuticals (CRBP) Gets a Buy Rating from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP), with a price target of $3.00. The company’s shares closed last Tuesday at $1.22, close to its 52-week low of $0.91.

According to, Fein is a 4-star analyst with an average return of 4.9% and a 44.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Phasebio Pharmaceuticals, and Zentalis Pharmaceuticals.

Currently, the analyst consensus on Corbus Pharmaceuticals is a Hold with an average price target of $2.18.

See today’s analyst top recommended stocks >>

Based on Corbus Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $286.3K and GAAP net loss of $38.11 million. In comparison, last year the company earned revenue of $29.09 million and had a net profit of $2.15 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts